Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-662 · 1 trial · 1 indication
Protein C is a vitamin K-dependent plasma protein and is an important component of the coagulation system. Protein C activity level was measured by chromogenic assays. Protein C activity level of TAK-662 was reported.
t1/2 of TAK-662 was reported.
IR of TAK-662 was reported measured in terms of international unit per milliliter/ international unit per kilogram (IU/mL)/(IU/kg).
IVR corrected for plasma was determined using the formula: IVR (percentage \[%\])= (Maximum observed plasma concentration (Cmax) \[IU/mL\] - Concentration (C) pre-infusion \[IU/mL\]) \* Plasma volume pre-infusion (PV) milliliter (mL)/ Dose (international unit \[IU\])\*100 where Cmax was the observed Cmax value before baseline correction. IVR of TAK-662 measured in terms of percentage was reported.
AUClast of TAK-662 was reported measured in terms of international unit\*hour per milliliter (IU\*h/ml).
AUC0-infinity of TAK-662 was reported.
Cmax of TAK-662 was reported.
Tmax of TAK-662 was reported.
| Arm | Type | Description |
|---|---|---|
| TAK-662 80 IU/kg | EXPERIMENTAL | TAK-662 80 international unit (IU)/kg, single intravenous infusion over 15 minutes on Day 1. In the extension part, dose of TAK-662 will be modified per participants. TAK-662 is Protein C Concentrate, which is a lyophilized, sterile concentrate of human protein C. |
| Name | Type | Description |
|---|---|---|
| TAK-662 | DRUG | Lyophilized, sterile concentrate of human protein C |
Inclusion Criteria: PK Part: 1. Male and female participants with Japanese nationality. 2. A diagnosis of congenital protein C deficiency (homozygous or compound heterozygous). 3. Asymptomatic participant. 4. Oral anticoagulants allowed to be received. Extension part: 1. Participants who partici...
TAK-662 is an investigational small molecule being developed for the treatment of congenital protein C deficiency, a rare hematologic disorder. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
TAK-662 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker symbol TAK. The company is conducting clinical research on this investigational therapy for congenital protein C deficiency.
TAK-662 is in Phase 1 clinical development. It is an investigational drug and has not been approved for commercial use. The Phase 1 study has been completed, and the drug remains under clinical investigation.
TAK-662 has one completed Phase 1 clinical trial, NCT04984889, which studied the drug in Japanese patients with congenital protein C deficiency. The trial enrolled 5 participants and was an uncontrolled, non-randomized study.
TAK-662 is the primary name for this investigational drug. No alternative names have been reported for this compound in clinical development.